Abstract
Background
Desmoid tumors (aggressive fibromatosis) are rare soft tissue tumors which frequently recur after surgery. Desmoid tumors arise from musculoaponeurotic tissue in the extremities, head and neck, abdominal wall, or intra-abdominally. Our aim was to examine the outcome of radiotherapy of desmoid tumors in a single institution series.
Patients and methods
We evaluated 41 patients with desmoid tumors treated with 49 radiotherapies between 1987 and 2012. Radiologic images for response evaluation were reassessed and responses to treatment registered according to RECIST criteria 1.1. For patients with local failures radiation dose distribution was determined in each local failure volume using image co-registration. Recurrences were classified as in-target, marginal, or out-of-target. Prognostic factors for radiotherapy treatment failure were evaluated.
Results
Radiotherapy doses varied from 20–63 Gy (median 50 Gy) with a median fraction size of 2 Gy. The objective response rate to definitive radiotherapy was 55% (12/22 patients). Median time to response was 14 months. A statistically significant dose-response relation for definitive and postoperative radiotherapy was observed both in univariate (p-value 0.002) and in multivariate analysis (p-value 0.02) adjusted for potential confounding factors. Surgery before radiotherapy or surgical margin had no significant effect on time to progression. Nine of 11 (82%) local failures were classified as marginal and two of 11 (18%) in-target. None of the recurrences occurred totally out-of-target.
Conclusions
Radiotherapy is a valuable option for treating desmoid tumors. Radiotherapy dose appears to be significantly associated to local control.
Zusammenfassung
Hintergrund
Desmoide (aggressive Fibromatosen) sind seltene Weichteiltumore der muskulären Membranen von Kopf, Hals, Extremitäten und Bauchwand. Ziel war es, die Wirksamkeit der Strahlentherapie bei aggressiver Fibromatose an einer einzelnen Klinik zu untersuchen.
Patienten und Methode
Ausgewertet wurden 41 Patienten mit aggressiver Fibromatose, die zwischen 1987 und 2012 mit 49 Strahlentherapien behandelt wurden. Das Ansprechen wurde anhand der radiologischen Aufnahmen neu beurteilt und der Behandlungserfolg gemäß RECIST-1.1-Kriterien registriert. Für Patienten mit Lokalrezidiv wurde die Dosisverteilung der Radiotherapie durch Fusion von diagnostischen CT- und MRT-Bildern mit den Planungs-CT-Aufnahmen für jedes Lokalrezidiv bestimmt. Die Rezidive wurden je nach Lage eingeteilt in: innerhalb, am Rande und außerhalb des ehemaligen Bestrahlungsvolumens gelegen. Prognostische Faktoren für ein Therapieversagen wurden ausgewertet.
Ergebnisse
Die Gesamtdosen der Strahlentherapie lagen zwischen 20 und 63 Gy (Median 50 Gy) mit einer medianen Fraktionierung von 2 Gy. Die objektive Ansprechrate war 55 % (12/22 Patienten). Die mediane Zeit bis zum Therapieerfolg betrug 14 Monate. Eine statistisch signifikante Dosis-Wirkungs-Beziehung für die definitive und die postoperative Strahlentherapie wurde sowohl in der univariaten (p-Wert 0,002) als auch in der für potentielle Störfaktoren korrigierenden multivariaten Analyse (p-Wert 0,02) beobachtet. Neun von 11 (82 %) Lokalrezidiven wurden als Feldrandrezidive und zwei von 11 (18 %) als innerhalb des Bestrahlungsfelds liegende Rezidive bewertet. Kein Lokalrezidiv trat komplett außerhalb des Bestrahlungsfelds auf.
Schlussfolgerung
Die Strahlentherapie ist eine wertvolle Therapiewahl zur Behandlung aggressiver Fibromatosen. Die Strahlentherapiedosis hat einen signifikanten Einfluss auf die lokale Kontrolle.
Similar content being viewed by others
References
Groen EJ, Roos A, Muntinghe FL et al (2008) Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol 15:2439–2450
Heiskanen I, Jarvinen HJ (1996) Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment. Int J Colorectal Dis 11:157–162
Cheon SS, Nadesan P, Poon R et al (2004) Growth factors regulate beta-catenin-mediated TCF-dependent transcriptional activation in fibroblasts during the proliferative phase of wound healing. Exp Cell Res 293:267–274
Clark SK, Neale KF, Landgrebe JC et al (1999) Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 86:1185–1189
Fiore M, Rimareix F, Mariani L et al (2009) Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 16:2587–2593
Bonvalot S, Ternes N, Fiore M et al (2013) Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol 20:4096–4102
Briand S, Barbier O, Biau D et al (2014) Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. J Bone Joint Surg Am 96:631–638
Colombo C, Miceli R, Le Pechoux C et al (2015) Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer 51:186–192
Group ESESNW (2014) Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii102–iii112
Kasper B, Baumgarten C, Bonvalot S et al (2015) Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise – a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer 51:127–136
von Mehren M, Benjamin RS, Bui MM et al (2016) NCCN Clinical Practise Guidelines in Oncology (NCCN Guidelines) Soft Tissue Sarcoma Version 2.2016
Escobar C, Munker R, Thomas JO et al (2012) Update on desmoid tumors. Ann Oncol 23:562–569
Lazar AJ, Tuvin D, Hajibashi S et al (2008) Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173:1518–1527
Lewis JJ, Boland PJ, Leung DH et al (1999) The enigma of desmoid tumors. Ann Surg 229:866–872 (discussion 872–3)
Guadagnolo BA, Zagars GK, Ballo MT (2008) Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys 71:441–447
Chao KS, Ozyigit G, Tran BN et al (2003) Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 55:312–321
Sampo MM, Tuomikoski L, Tarkkanen M et al (2013) Marginal miss or radioresistance? The pattern of local recurrence after operation and 3D planned radiation treatment in soft tissue sarcoma of the extremities and the limb girdles; an analysis based on image fusion. Acta Oncol 53(4):557–562. doi:10.3109/0284186x.2013.844355
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Alektiar K, Berry S (2011) Quantitative dosimetric analysis of patterns of local relapse after adjuvant IMRT for primary extremity sarcoma. Int J Radiat Oncol Biol Phys 81:S119 (Abstract)
Gronchi A, Colombo C, Le Pechoux C et al (2014) Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm – a position paper from the Italian and the French Sarcoma Group. Ann Oncol 25:578–583
Nuyttens JJ, Rust PF, Thomas CR Jr. et al (2000) Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer 88:1517–1523
Zlotecki RA, Scarborough MT, Morris CG et al (2002) External beam radiotherapy for primary and adjuvant management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys 54:177–181
Gluck I, Griffith KA, Biermann JS et al (2011) Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 80:787–792
Murphey MD, Ruble CM, Tyszko SM et al (2009) From the archives of the AFIP: musculoskeletal fibromatoses: radiologic-pathologic correlation. Radiographics 29:2143–2173
Walker EA, Petscavage JM, Brian PL et al (2012) Imaging features of superficial and deep fibromatoses in the adult population. Sarcoma 2012:215810
Yao X, Corbett T, Gupta AA et al (2014) A systematic review of active treatment options in patients with desmoid tumours. Curr Oncol 21:e613–e629
Goy BW, Lee SP, Eilber F et al (1997) The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int J Radiat Oncol Biol Phys 39:659–665
Spear MA, Jennings LC, Mankin HJ et al (1998) Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 40:637–645
Ballo MT, Zagars GK, Pollack A et al (1999) Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 17:158–167
Rüdiger HA, Ngan SYK, Ng M et al (2010) Radiation therapy in the treatment of desmoid tumours reduces surgical indications. Eur J Surg Oncol 36:84–88
Keus RB, Nout RA, Blay JY et al (2013) Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis – an EORTC STBSG and ROG study (EORTC 62991–22998). Ann Oncol 24(10):2672–2676. doi:10.1093/annonc/mdt254
Ihalainen HR, Koljonen V, Bohling TO et al (2015) The desmoid tumour: local control after surgical treatment. J Plast Surg Hand Surg 49:19–24
Baumert BG, Spahr MO, Von Hochstetter A et al (2007) The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiat Oncol 2:12
Ballo MT, Zagars GK, Pollack A (1998) Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 42:1007–1014
Schulz-Ertner D, Zierhut D, Mende U et al (2002) The role of radiation therapy in the management of desmoid tumors. Strahlenther Onkol 178:78–83
Schmitt G, Mills EE, Levin V et al (1992) Radiotherapy of aggressive fibromatosis. Eur J Cancer 28A:832–835
Reitamo JJ, Hayry P, Nykyri E et al (1982) The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol 77:665–673
Acknowledgements
Finska Läkaresällskapet supported the corresponding author and the study was supported from the EVO funds. We thank Annette Beule, MD PhD and Claudia Lundgren, MD for writing and editing the German abstract.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
K. Santti, A. Beule, L. Tuomikoski, M. Rönty, A.-S. Jääskeläinen, K. Saarilahti, H. Ihalainen, M. Tarkkanen, and C. Blomqvist declare that they have no competing interests.
Ethical standards
This article does not contain any studies with human participants or animals performed by any of the authors.
Caption Electronic Supplementary Material
Rights and permissions
About this article
Cite this article
Santti, K., Beule, A., Tuomikoski, L. et al. Radiotherapy in desmoid tumors. Strahlenther Onkol 193, 269–275 (2017). https://doi.org/10.1007/s00066-016-1091-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-016-1091-8